Market News & Trends
Infinity Pharmaceuticals Pays Millennium $15 Million
 Infinity Pharmaceuticals, Inc. recently announced that the company amended its development and license agreement with Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Company…
Perrigo Acquires Remaining Stake in Drug Development Company for Nearly $45 Million
 Perrigo Company recently announced it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately held,…
Ultragenyx Secures $75 Million for Ultra-Rare Diseases
 Ultragenyx Pharmaceutical Inc. recently announced the successful completion of a $75-million Series B round financing led by Adage Capital Partners, LP. Joining Adage as…
Atlantic Pharmaceuticals Makes Major Announcement
 Atlantic Pharmaceuticals, Inc. recently announced that new patents have been issued by the USPTO relating to its tamper-resistant SMART/Script drug delivery platform. US Patent…
Blend Therapeutics Secures $16 Million
 Blend Therapeutics, Inc. recently announced it has secured a $16-million Series B financing. Blend is pioneering an integrative model for discovering novel molecular entities…
Pisgah Laboratories Receives Patent for Abuse-Deterrent Technology
 Pisgah Laboratories, Inc. recently announced it has received US Patent No. 8,334,322 from the United States Patent and Trademark Office for innovative, abuse-deterrent forms…
Radius & 3M Announce Exclusive Agreement
 Radius Health, Inc. and 3M Drug Delivery Systems recently announced an exclusive partnership agreement for development and commercialization of BA058-transdermal (TD). BA058 is a…
Raptor Signs $50-Million Agreement With HealthCare Royalty Partners
 Raptor Pharmaceutical Corp. recently announced it has signed a $50-million loan agreement with HealthCare Royalty Partners to help fund the commercialization of PROCYSBI, the…
12/27/2012
Radius & 3M Announce Exclusive Agreement Radius Health, Inc. and 3M Drug Delivery Systems recently announced an exclusive partnership agreement for development and commercialization of…
Aptuit & Alios BioPharma to Collaborate
 Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, recently announced that Aptuit and Alios BioPharma, South San Francisco, California, are collaborating in lead…
12/19/2012
Biogen Idec & Eisai Inc. Form Strategic Alliance Biogen Idec and Eisai Inc. recently announced a strategic alliance that will bolster the manufacturing capabilities of…
Aptalis Pharmaceutical Technologies Announces Approval
Aptalis Pharmaceutical Technologies recently announced that the European Commission granted marketing authorization for a new pediatric indication of a new oral granule formulation of…
Biogen Idec & Eisai Inc. Form Strategic Alliance
Biogen Idec and Eisai Inc. recently announced a strategic alliance that will bolster the manufacturing capabilities of both companies' Research Triangle Park (RTP)-based facilities.…
Catalent & UMN Pharma Announce Biosimilar Development Collaboration
Catalent Pharma Solutions and UMN Pharma Inc. recently announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell…
FDA Panel Rejects Painkiller Drug
Zogenix, Inc. recently announced that the US FDA Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) voted 2 to 11 (with one abstention) against…
Ligand Pharmaceuticals & Pfizer Get PDUFA Date
Pfizer Inc. and Ligand Pharmaceuticals Incorporated recently announced that the US FDA accepted for review an NDA for bazedoxifene/conjugated estrogens (BZA/CE), a potential new…
The Medicines Company Licenses BMS' Device for $105 Million
The Medicines Company and Bristol-Myers Squibb Company recently announced that the companies have signed a global license and 2-year collaboration for Recothrom, a recombinant…
Pearl Therapeutics Issued US Patent on Co-Suspension Formulation Technology
Pearl Therapeutics Inc. recently announced that the US Patent and Trademark Office has issued a patent on its novel co-suspension formulation technology for inhaled combinations.…
Teva Enters $376-Million Deal for Xenon's Pain Drug
Teva Pharmaceutical Industries Ltd and Xenon Pharmaceuticals Inc. recently announced they have entered into a collaborative development and exclusive worldwide license for XEN402, which is…
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs
The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor…
